ImmuneWorks is a clinical stage biotechnology company with deep expertise in immunology and lung disease. The Company, based in Indianapolis, was founded in 2006, receiving an exclusive license from Indiana University. ImmuneWorks is developing IW001, using an immune modulation approach to treat idiopathic pulmonary fibrosis ("IPF"), an orphan disease indication with significant unmet medical need. ImmuneWorks has completed a Phase 1 trial in IPF patients, which demonstrated safety and evidence of clinical efficacy via oral administration of IW001.
View Top Employees from ImmuneWorks, Inc.| Website | https://www.immuneworks.com |
| Revenue | $3 million |
| Employees | 2 (0 on RocketReach) |
| Founded | 2006 |
| Address | 351 W 10th St, Ste 251, Indianapolis, Indiana 46202, US |
| Phone | (317) 278-0205 |
| Technologies |
JavaScript,
HTML,
PHP
+194 more
(view full list)
|
| Industry | Biotechnology, Pharmaceuticals, Healthcare, Science and Engineering, Therapeutic Devices, Health Care, Drug Manufacturing & Research |
| Competitors | Anokion, Leap Therapeutics, Neuraltus Pharmaceuticals, Neuren Pharmaceuticals, OxThera |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular ImmuneWorks, Inc. employee's phone or email?
ImmuneWorks, Inc. Questions
The ImmuneWorks, Inc. annual revenue was $3 million in 2023.
ImmuneWorks, Inc. is based in Indianapolis, Indiana.
The NAICS codes for ImmuneWorks, Inc. are [3254, 32541, 32, 325].
The SIC codes for ImmuneWorks, Inc. are [28, 283].
Related Companies
